Since the oral form of the peptide is not available commercially and injection of the peptide is not approved by the FDA, no metabolism experiments could be performed in humans If we go back to the 2014 review of six randomized, double-blind, placebo-controlled trials involving just over 900 patients, we see the following results: AOD9604 had no effect on serum IGF-1 levels, which confirms the hypothesis that AOD9604 does not act via IGF-1
Think of it like this: Hot water is like a magnifying glass for the sun
Avoiding these will save you time, money, and frustration
They are based on the latest medical knowledge and advice from experts around the world
This depends on their health and how they react to the treatment
The compound may work synergistically with NAD+ precursors like NMN or NR, potentially enhancing metabolic benefits